ME

Michael Ehlers

General Partner at ATP

Cambridge, Massachusetts

Overview

Work Experience

  • Chief Scientific Officer, General Partner

    2024 - Current

  • Chief Scientific Officer, Venture Partner

    2019 - 2024

    Apple Tree Partner's (ATP’s) unique model follows the science, brings together the best teams, and deploys significant capital to create and build the next generation of innovative biotechnology companies.

  • Founder, President, and Chief Executive Officer

    2023

    Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.

  • Founder and Board Chair

    2022 - 2023

    Scientific and corporate leadership of research stage biotechnology company developing designer synthetic RNA therapeutics and RNA exon editing therapies for ophthalmological, neurological, neuromuscular, and rare diseases.

  • Founder, President and Chief Executive Officer

    2020 - 2022

    Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.

  • Co-Founder and Board Chair

    2021

    Scientific and corporate leadership of research stage biotechnology company developing novel self-replicating RNA therapies for cancer, autoimmune disorders, and infectious diseases.

  • Co-Founder and Board Chair

    2020

    Scientific and corporate leadership of research stage biotechnology company developing novel immunotherapies for the treatment of diverse cancers.

  • Founder and Board Chair

    2023 - 2023

    Scientific and corporate leadership of research stage biotechnology company developing non-viral gene therapies for ophthalmological diseases.

  • Founder, President, and Chief Executive Officer

    2020 - 2023

    Led all activities at a cutting-edge start-up biotechnology company focused on non-viral gene therapy. Deploying molecular biology and bioengineering platforms to create breakthrough therapies in ophthalmology.

  • Chief Executive Officer

    2019 - 2020

    Led a cutting-edge start-up biotech company focused on gene therapy and genetic medicines for patients with severe inherited diseases.

  • Executive Vice President

    2016 - 2019

    led global R&D for a cutting edge, industry-leading biotechnology company

  • Group Senior Vice President, BioTherapeutics

    2015 - 2016

    Lead R&D activites in a large division of a leading biopharmaceutical company.

  • Senior Vice President, Chief Scientific Officer for Neuroscience

    2010 - 2016

    lead global research and development in neuroscience to create innovative medicines that effectively treat brain disorders

  • SVP, CSO Neuroscience

    2010 - 2011

  • SVP, CSO Neuroscience

    2010 - 2011

  • Investigator

    2005 - 2010

  • Professor of Neurobiology

    1998 - 2010

Relevant Websites